Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

Stage III non-small cell lung cancer (NSCLC) has a dismal prognosis, with only 15–20% of patients alive at 5 years after concomitant chemo–radiotherapy, which represents the standard treatment. Targeting immune-checkpoint inhibitors represents a standard option for advanced NSCLC. Improvements in un...

Descripción completa

Detalles Bibliográficos
Autores principales: Botticella, Angela, Mezquita, Laura, Le Pechoux, Cecile, Planchard, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831969/
https://www.ncbi.nlm.nih.gov/pubmed/31686616
http://dx.doi.org/10.1177/1753466619885530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831969/
https://www.ncbi.nlm.nih.gov/pubmed/31686616
http://dx.doi.org/10.1177/1753466619885530

Ejemplares similares